The biologic information from GPS "adds to our ability to make a precision decision for the patient," Dr. Klein said. "It doesn’t replace grade stage and PSA. It doesn’t replace clinical judgment. It’s another piece of very powerful information that can influence patient decision-making."
He went on to note that a test like the GPS could reduce the burden of determining eligibility for active surveillance. "Typically, in most practices, if you’re going to be considered for active surveillance after initial biopsy that shows low-grade disease, you have a second biopsy," Dr. Klein said. "I believe that the rationale is established that you could substitute this kind of biomarker for a second biopsy."
Dr. Klein disclosed that he has received research support and/or consulting fees from Genomic Health, GenomeDx Biosciences, and Metamark.